Management of Transgenderism

The document discussed the management of transgenderism, highlighting that it was poorly understood both mechanistically and clinically. Awareness had been increasing due to greater societal acceptance and available hormonal treatments. Therapeutic options included hormone and surgical treatments, though these could be limited by high costs and insurance coverage. For male-to-female (MTF) transitions, treatments included estrogens, finasteride, spironolactone, and GnRH analogs, along with various surgical options. For female-to-male (FTM) transitions, treatments included testosterone and GnRH analogs, with surgical options like mammoplasty and phalloplasty. Medical therapy could start in early puberty, but long-term effects were unknown. Counseling and medical monitoring were essential for all patients considering treatment.